Timing of hepatitis B vaccine after transplant
Compares two hepatitis B vaccine schedules, starting at 3 or 6 months after transplant.
Plain-language title generated from the registry record
Registry title: Optimal Timing of Hepatitis B Vaccination After Transplants
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 3
Where in China
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT06888479
- Record updated
- 21 March 2025
- Original description
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.Read full original descriptionShow less
Optimal Timing of Hepatitis B Vaccination After Transplants: a Randomized Clinical Study
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different vaccination schedules (initiated at 3 or 6 months after transplantation) in patients with different immune reconstitution status.
Inclusion: Patients must be ≥ 16 years old; Patients receiving hematopoietic cell transplantation; Patients achieving complete molecular remission; Patients or their guardians have to sign an informed consent form before the start of the research procedure.
Exclusion: Donors' HBV-DNA or HBsAg are positive; Patients' HBV-DNA or HBsAg are positive before transplantation or < 3 months after transplantation; Patients who are unable to comply with the research treatments and monitoring requirements due to mental or other medical conditions; Multiple transplantations; Patients who are ineligible for the study due to other reasons which would cause unacceptable risks to the patients.